Breakthrough Cancer Vaccine Shows Promise in Melanoma Trial

Pharmaceutical giants Merck and Moderna have made a groundbreaking breakthrough in cancer treatment using personalized vaccines.

Their joint effort, known as intismeran autogene, involves combining Merck's immunotherapy drug Keytruda with a customized mRNA vaccine to train the immune system to target specific mutations found on a patient's tumor.

After a trial involving over 1,000 patients with localized melanoma, results showed that the treatment significantly reduced the risk of cancer recurrence and spread.